Neoplasms Clinical Trial
Official title:
Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?
| Verified date | September 2018 |
| Source | Royal Marsden NHS Foundation Trust |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of this study is to determine whether greater rectal cancer downstaging and
regression occurs when surgery is delayed to 12 weeks after completion of
radiotherapy/chemotherapy compared to 6 weeks.
Hypothesis: Greater downstaging and tumour regression is observed when surgery is delayed to
12 weeks after completion of CRT compared to 6 weeks.
| Status | Active, not recruiting |
| Enrollment | 237 |
| Est. completion date | December 8, 2019 |
| Est. primary completion date | December 8, 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Aged > 18 - Informed written consent - Histological confirmation of adenocarcinoma of rectum - Undergoing pre-operative radiotherapy/ chemotherapy - Completion of pre-operative treatment Exclusion Criteria: - Aged < 18 - Absence of pre-operative RT/CT - Medical/ psychiatric conditions that compromise the patients ability to give informed consent - Contra-indications to MRI, i.e. hip prothesis, cardiac pacemaker |
| Country | Name | City | State |
|---|---|---|---|
| Brazil | Hospital Alemão Oswaldo Cruz | Sao Paulo | |
| Canada | Jewish General Hospital | Montreal | Quebec |
| Cyprus | Bank of Cyprus Oncology Centre | Nicosia | |
| United Kingdom | Royal United Hospital NHS Trust | Bath | |
| United Kingdom | Sandwell and West Birmingham Hospitals NHS Trust | Birmingham | |
| United Kingdom | Epsom and St Helier's Hospitals NHS Trust | Carshalton | Surrey |
| United Kingdom | St Richard's Hospital | Chichester | West Sussex |
| United Kingdom | Essex County Hospital | Colchester | Essex |
| United Kingdom | Croydon University Hospital | Croydon | |
| United Kingdom | Dorset County Hospital NHS Foundation Trust | Dorchester | Dorset |
| United Kingdom | County Durham and Darlington NHS Trust (University Hospital of North Durham) | Durham | County Durham |
| United Kingdom | Medway NHS Foundation Trust | Gillingham | Kent |
| United Kingdom | James Paget University Hospitals NHS Foundation Trust | Great Yarmouth | Norfolk |
| United Kingdom | North West London Hospitals NHS Trust (Northwick Park Hospital) | Harrow | Middlesex |
| United Kingdom | Hinchingbrooke Hospital | Huntingdon | Cambridgeshire |
| United Kingdom | St Bartholomew's Hospital | London | |
| United Kingdom | St George's Healthcare NHS Trust | London | |
| United Kingdom | Pennine Acute Hospitals NHS Trust | Manchester | |
| United Kingdom | Poole Hospital NHS Foundation Trust | Poole | Dorset |
| United Kingdom | Portsmouth Hospitals NHS Trust (Queen Alexandra Hospital) | Portsmouth | Hampshire |
| United Kingdom | North Tees and Hartlepool NHS Trust (University Hospital of North Tees) | Stockton-on-Tees | County Durham |
| United Kingdom | Royal Marsden NHS Trust | Sutton | |
| United Kingdom | Mid Yorkshire Hospitals NHS Trust (Pinderfields Hospital) | Wakefield | West Yorkshire |
| Lead Sponsor | Collaborator |
|---|---|
| Royal Marsden NHS Foundation Trust |
Brazil, Canada, Cyprus, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI]. | 6-12 weeks | ||
| Secondary | Tumour response using SUV measurements [PET/CT], N downstaging and Tumour Regression Grade downstaging [on MRI]. | 3 months | ||
| Secondary | Difference in proportion of patients in each arm undergoing sphincter saving surgery. | 3 months | ||
| Secondary | Morbidity, 30 day mortality and CRM (circumferential resection margin) positivity. | 3 months | ||
| Secondary | An analysis will also be undertaken using multivariate and linear regression analysis to evaluate the association of ypT and ypN stage as a potential independent predictors of SUV (max) baseline and after radiotherapy (pre-surgery) in the two arms. | 3 months | ||
| Secondary | Local and distant recurrence rates. | 5 years | ||
| Secondary | Radiotherapy related toxicity rates. | 5 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |